Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519136 | 0.90 | MAPK14 (0.49) | MAPK14MAOB | |
| SCHEMBL3524686 | 0.86 | MAPK14 (0.46) | MAPK14MAOB | |
| SCHEMBL13185698 | 0.85 | MAPK14 (0.46) | MAPK14PTGER1 | |
| SCHEMBL3523377 | 0.83 | MAPK14 (0.57) | MAPK14PTGER1 | |
| SCHEMBL3527007 | 0.82 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL3521114 | 0.80 | MAPK14 (0.52) | MAPK14PTGER1MAOBKDM5AKDM4C | |
| SCHEMBL3523581 | 0.80 | MAPK14 (0.51) | MAPK14PTGER1MAOBGLP1RKDM5A | |
| SCHEMBL5443627 | 0.80 | MAPK14 (0.58) | MAPK14PTGER1MAOB | |
| SCHEMBL3521145 | 0.79 | PTGER1 (0.41) | MAPK14PTGER1MAOBGLP1RKDM5A | |
| SCHEMBL3521142 | 0.79 | PTGER1 (0.41) | MAPK14PTGER1MAOBGLP1RKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | claimed |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-20240327357-A1 | 4-((6-OXOPYRIMIDIN-1(6H)-YL)METHYL)BENZOIC ACID AS AN INDUCER OF Z A1AT SECRETION FOR TREATING AATD | OXFORD FINANCE LLC | 2024-10-03 | — | — | US | disclosed |
| WO-2021255436-A1 | 4-((6-OXOPYRIMIDIN-1(6H)-YL)METHYL)BENZOIC ACID AS AN INDUCER OF Z A1 AT SECRETION FOR TREATING AATD | Z Factor Limited (GB) | 2021-12-23 | — | — | WO | disclosed |
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327357-A1 | 4-((6-OXOPYRIMIDIN-1(6H)-YL)METHYL)BENZOIC ACID AS AN INDUCER OF Z A1AT SECRETION FOR TREATING AATD | SERPINA2, SERPINB6, SERPINB1 | MAPK14 4195/4885PTGER1 2611/4885MAOB 1347/4885 |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | SERPINA2, SERPINB1, SERPINE1 | MAPK14 2501/4885PTGER1 1434/4885MAOB 1913/4885 |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885PTGER1 245/4885MAOB 1718/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885PTGER1 215/4885MAOB 1814/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885PTGER1 245/4885MAOB 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.